Navigation Links
New approach for the treatment of malignant brain tumors

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Zrich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.

In addition, the Working Group headed by Professor Dr. Wolfgang Wick, Medical Director of the Department of Neurooncology at Heidelberg University Hospital and Head of the Neurooncology Unit at the DKFZ, Professor Dr. Michael Weller, Chairman of the Department of Neurology at the University Hospital Zurich, and Prof. Andreas von Deimling, Medical Director of the Department of Neuropathology at Heidelberg University Hospital and Head of the Neuropathology Unit at the DKFZ, identified a new factor that is indicative of a positive prognosis regardless of the form of treatment. The results of the study were published in the Journal of Clinical Oncology.

In Germany, around 4,500 people a year develop a glioma, a malignant brain tumor. Some 5 percent of primary brain tumors are what are known as anaplastic gliomas. They respond to treatment somewhat better than most other malignant brain tumors. The mean survival time in the study was > 80 months. As the tumors can branch out widely into the surrounding tissue, they cannot be completely removed. The subsequent therapy in the form of combined radiochemotherapy (radiation and chemotherapy) is the current standard treatment, but it is associated with a risk of long-term toxicity to healthy brain tissue, causing the patient to lose cognitive abilities.

Primary chemotherapy as an equivalent treatment option

Two studies recently conducted by the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) have shown that combined radiochemotherapy according to current standard practice does not yield better therapy results than radiotherapy alone. The NOA (Neurooncology Working Group) study has now also proven that chemotherapy alone after surgical removal of the tumor has an equivalent result. "This additional treatment option facilitates the further development of the treatment plan in new combinations with the long-term goal of improving the survival rate," says Professor Wolfgang Wick.

Gene mutation predicts improved outcome

Depending on their tissue composition, anaplastic gliomas are classified in different sub-groups which are assumed to have different prognoses. However, in this study, the previously distinct sub-groups of oligodendroglial tumors had an identical clinical course. With the aid of extensive molecular pathology studies of extirpated tumor tissue, the researchers identified a new prognosis factor called IDH1 mutation (gene mutation of isocitrate dehydrogenase). It is indicative, irrespective of the type of tissue of the anaplastic glioma and irrespective of treatment, of a better prognosis. The researchers proved that the already known prognosis factor "MGMT promoter methylation" is not predictive for chemotherapy, but did have prognostic value for chemotherapy as well as for radiation alone. "The results are relevant not only for clinical routine, but for current study designs of the large study networks EORTC and RTOG as well," explained Professor Wick.


Contact: Prof. Dr. med. Wolfgang Wick
University Hospital Heidelberg

Related medicine news :

1. Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop
2. Workshop targets control-theoretic approaches for agent-based models
3. Experimental approach may reverse rheumatoid arthritis and osteoporosis
4. Details Emerge About Approach, Results of First US Face Transplant
5. Baucus Approach to Financing Health Care Reform Step in Right Direction
6. Bitemark evidence and analysis should be approached with caution, according to UB study
7. Economic Conditions Signal Long-Term Shift in Rx Benefit Approach
8. WorldatWork Publishes Axiom Consulting Partners' Article on ‘Planning for the New Normal', an Alternative Approach to Compensation Planning
9. A Mediterranean Approach to Flavorful Living
10. Approach Group, Inc. and M. Beacon Enterprises, LLC Announce Strategic Partnership to Provide End-to-End Business Continuity Planning
11. Breakthroughs in Eye Care Products Offer Fresh Approach for Soothing Eyes
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... Secura Consultants has prided itself for not only fulfilling the needs of advisers ... solutions at an affordable price and providing top-tier customer service. However, there's always ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... Santa Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine ... dinner meeting. They observed that both STEMI and Sepsis conditions present in similar ways ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think ... customers choose to buy during the Black Friday and Cyber Monday massage chair ... to search the Internet high and low to find the best massage chair deals, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology: